Baxalta Announces FDA Approval of ADYNOVATE Treatment for Hemophilia A

Baxalta Incorporated BXLT announced Friday that the U.S. Food and Drug Administration (FDA) has approved ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A. ADYNOVATE is built on the full-length ADVATE [Antihemophilic Factor (Recombinant)] molecule, a leading treatment for hemophilia A with more than 12 years of real-world patient experience. This press release has an accompanying Smart Marketing Page providing further details about the organization, products and services introduced below. You can access the Smart Marketing Page via the following link: http://smp.businesswire.com/pages/baxalta-receives-fda-approval-for-adynovate See full press release